İçeriğe geç
akaturk Akademik ölçüm
Giriş Kayıt

Akademisyen

SEDAT ŞEN

DOÇENT

ONDOKUZ MAYIS ÜNİVERSİTESİ TIP FAKÜLTESİ DAHİLİ TIP BİLİMLERİ BÖLÜMÜ

  • Ana Dal Sağlık Bilimleri Temel Alanı
  • Yan Dal Nöroloji

Kayıtlı çıktılara kısa bakış — ayrıntılar aşağıda.

  • Makale 49
  • Proje 0
  • Kitap 12
  • Bildiri 28
  • Patent 0
  • Sanatsal 0
Scopus (SJR) Q1 32 Q2 12 Q3 11 Q4 3
WoS (JCR) Q1 13 Q2 28 Q3 7 Q4 8
TR Index 3 makale

Alan+yıl+tür normalize OpenAlex yüzdelik — Clarivate ESI / SciVal değildir.

Üst %1 makale 2
Üst %10 makale 8
Ort. yüzdelik 69.4%
Üst %1 payı 3.5%
Üst %10 payı 14.0%

Makaleler

YÖKSİS ve OpenAlex kaynak ayrımıyla makaleler; quartile ve TR Index ile daraltabilirsiniz.

Dizin filtreleri

Toplam 49 yayın

Scopus (SJR)
Q1 32 Q2 12 Q3 11 Q4 3
WoS (JCR)
Q1 13 Q2 28 Q3 7 Q4 8
TR Index
3 makale

Makale listesi

  1. 2026 Real-world effectiveness and safety of eculizumab in AQP4-IgG-positive neuromyelitis optica spectrum disorder. J Neurol DOI 10.1007/s00415-025-13608-w YÖKSİS SJR Q1 JCR Q1 OpenAlex 1.7%
  2. 2025 Exome sequencing reveals low-frequency and rare variant contributions to multiple sclerosis susceptibility in Turkish families SCIENTIFIC REPORTS DOI 10.1038/s41598-025-94691-x YÖKSİS SJR Q1 JCR Q1 OpenAlex 84.4%
  3. 2025 Safety and Efficacy of Cladribine in Patients Discontinuing Fingolimod Due to Elevated Transaminase Levels: The FinClad Study Multiple Sclerosis and Related Disorders DOI 10.1016/j.msard.2025.106578 YÖKSİS SJR Q1 JCR Q2 OpenAlex 79.7%
  4. 2025 Comparative efficacy of rituximab versus azathioprine in the treatment of MOG antibody-associated disease (MOGAD) Journal of Neuroimmunology DOI 10.1016/j.jneuroim.2025.578686 YÖKSİS SJR Q2 JCR Q3 OpenAlex üst %10 OpenAlex 92.3%
  5. 2025 Kappa-free light chain as a practical alternative to oligoclonal bands in the diagnosis of multiple sclerosis Multiple Sclerosis and Related Disorders DOI 10.1016/j.msard.2025.106377 YÖKSİS SJR Q1 JCR Q2 OpenAlex 89.3%
  6. 2025 Peripheral cytokine levels in patients with idiopathic parkinson’s disease undergoing subthalamic nucleus deep brain stimulation Scientific Reports DOI 10.1038/s41598-025-20730-2 YÖKSİS SJR Q1 JCR Q1 OpenAlex 74.1%
  7. 2025 A survey of diagnostic and treatment practices for multiple sclerosis in Turkey Multiple Sclerosis and Related Disorders DOI 10.1016/j.msard.2025.106823 YÖKSİS SJR Q1 JCR Q2 OpenAlex 36.6%
  8. 2024 Investigation of Novel Variants in Familial Multiple Sclerosis Through Family-based Association Tests and Segregation Analyses (S17.007) Neurology DOI 10.1212/WNL.0000000000206230 YÖKSİS SJR Q1 JCR Q1 OpenAlex 4.8%
  9. 2024 Impact of COVID-19 on pregnancy and fetal outcomes in women with multiple sclerosis Multiple Sclerosis Journal DOI 10.1177/13524585241232266 YÖKSİS SJR Q1 JCR Q1 OpenAlex 71.5%
  10. 2024 Natalizumab in Multiple Sclerosis: A Single Centre Real-World Study Journal of Multiple Sclerosis Research DOI 10.4274/jmsr.galenos.2024.2024-4-2 YÖKSİS OpenAlex 62.3%
  11. 2023 Sars-CoV2 infection in pregnant women with multiple sclerosis. Multiple Sclerosis Journal DOI 10.1177/13524585231176174 YÖKSİS SJR Q1 JCR Q1 OpenAlex 56.0%
  12. 2023 Teriflunomide and Time to Clinical Multiple Sclerosis in Patients With Radiologically Isolated Syndrome American Medical Association (AMA) DOI 10.1001/jamaneurol.2023.2815 YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 99.6%
  13. 2023 Clinical and Demographic Characteristics and Two-Year Efficacy and Safety Data of 508 Multiple Sclerosis Patients with Fingolimod Treatment Arch Neuropsychiatry DOI 10.29399/npa.28081 YÖKSİS SJR Q2 JCR Q2 OpenAlex 43.9%
  14. 2023 mRNA versus inactivated virus COVID-19 vaccines in multiple sclerosis: Humoral responses and protectivity—Does it matter? Multiple Sclerosis and Related Disorders DOI 10.1016/j.msard.2023.104761 YÖKSİS SJR Q1 JCR Q2 OpenAlex 88.7%
  15. 2023 Volumetric changes in hypothalamic subunits in patients with relapsing remitting multiple sclerosis Neuroradiology DOI 10.1007/s00234-023-03122-z YÖKSİS SJR Q1 JCR Q2 OpenAlex 86.3%
  16. 2023 Severe disease reactivation in seropositive neuromyelitis optica spectrum disorders patients after stopping eculizumab treatment Multiple Sclerosis and Related Disorders DOI 10.1016/j.msard.2023.104949 YÖKSİS SJR Q1 JCR Q2 OpenAlex 80.5%
  17. 2022 Coexistence of restless legs syndrome and multiple sclerosis aggravates anxiety and depression ARQUIVOS DE NEURO-PSIQUIATRIA DOI 10.1590/0004-282X-ANP-2020-0400 YÖKSİS SJR Q3 JCR Q4 OpenAlex 71.3%
  18. 2022 The Socioeconomic and Psychological Impact of the COVID-19 Pandemic on People with Multiple Sclerosis in Turkey Archives of Neuropsychiatry DOI 10.29399/npa.28189 YÖKSİS TR Index SJR Q3 JCR Q4 OpenAlex 52.0%
  19. 2022 Why are the First-Line Therapies Used as Injections Discontinued in the Treatment of Multiple Sclerosis? International Archives of Medical Research DOI 10.56484/iamr.1087921 YÖKSİS OpenAlex 9.4%
  20. 2022 A multiparametric score for assessing the individual risk of severe Covid-19 among patients with Multiple Sclerosis Multiple Sclerosis and Related Disorders DOI 10.1016/j.msard.2022.103909 YÖKSİS SJR Q1 JCR Q2 OpenAlex 73.2%

Akademisyenlere dön